BMS Urges Fed. Circ. To Revive Hepatitis B Drug Patent
Bristol-Myers Squibb pushed a Federal Circuit panel on Thursday to revive its patent covering the hepatitis B drug Baraclude, alleging a lower court applied improper legal standards when it found in...To view the full article, register now.
Already a subscriber? Click here to view full article